OliX Pharmaceuticals, Inc (KOSDAQ:226950)
South Korea
· Delayed Price · Currency is KRW 41,800
+750 (1.83%)
Apr 2, 2025, 3:30 PM KST
OliX Pharmaceuticals Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Net Income | -40,659 | -19,102 | -19,495 | -29,715 | -19,385 | Upgrade
|
| Depreciation & Amortization | 2,626 | 2,642 | 2,075 | 1,630 | 1,141 | Upgrade
|
| Loss (Gain) From Sale of Assets | -1,649 | 87.48 | -10,506 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -349.21 | -439.01 | 35.02 | -11.87 | 3,491 | Upgrade
|
| Loss (Gain) on Equity Investments | 8,223 | 900.91 | - | - | - | Upgrade
|
| Stock-Based Compensation | 1,163 | 1,226 | 1,594 | 1,932 | 512.81 | Upgrade
|
| Other Operating Activities | 4,396 | 668.74 | 4,066 | 4,750 | 517.8 | Upgrade
|
| Change in Accounts Receivable | 3,558 | -3,567 | -73.03 | - | - | Upgrade
|
| Change in Inventory | -85.85 | 188.76 | -283.04 | -69.96 | 61.65 | Upgrade
|
| Change in Other Net Operating Assets | -5,268 | -3,774 | -8,095 | 2,431 | 9,901 | Upgrade
|
| Operating Cash Flow | -28,045 | -21,168 | -30,683 | -19,054 | -3,759 | Upgrade
|
| Capital Expenditures | -13,465 | -8,826 | -2,233 | -1,290 | -786.48 | Upgrade
|
| Sale of Property, Plant & Equipment | 3,248 | 54.34 | 110.04 | 30.6 | - | Upgrade
|
| Cash Acquisitions | - | - | -1,387 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -170.16 | -239.11 | -301.41 | 164.38 | -375.08 | Upgrade
|
| Investment in Securities | 10,021 | 43,152 | -51,115 | 41,373 | -29,690 | Upgrade
|
| Other Investing Activities | 247.85 | 224.94 | -56.54 | -129.21 | -480.61 | Upgrade
|
| Investing Cash Flow | 973.56 | 34,366 | -54,764 | 15,473 | -31,420 | Upgrade
|
| Long-Term Debt Issued | 19,700 | 23,600 | - | 20,000 | 29,050 | Upgrade
|
| Long-Term Debt Repaid | -1,143 | -30,057 | -786.04 | -382.65 | -114.04 | Upgrade
|
| Net Debt Issued (Repaid) | 18,557 | -6,457 | -786.04 | 19,617 | 28,936 | Upgrade
|
| Issuance of Common Stock | - | 474.65 | - | 706.28 | 12,779 | Upgrade
|
| Other Financing Activities | -15.29 | -127.81 | -166.04 | 1,732 | -55.15 | Upgrade
|
| Financing Cash Flow | 18,541 | -6,110 | 56,048 | 26,555 | 41,660 | Upgrade
|
| Foreign Exchange Rate Adjustments | 430.69 | -35.09 | -7.87 | 32.94 | -107.1 | Upgrade
|
| Net Cash Flow | -8,099 | 7,052 | -29,406 | 23,008 | 6,374 | Upgrade
|
| Free Cash Flow | -41,510 | -29,995 | -32,916 | -20,344 | -4,546 | Upgrade
|
| Free Cash Flow Margin | -731.17% | -175.77% | -353.16% | -553.66% | -183.72% | Upgrade
|
| Free Cash Flow Per Share | -2464.53 | -2079.02 | -2402.08 | -1486.45 | -345.62 | Upgrade
|
| Cash Interest Paid | 544.13 | 1,225 | 785.3 | - | 17.75 | Upgrade
|
| Cash Income Tax Paid | -224.03 | 1,516 | 311.2 | 755.25 | -59.31 | Upgrade
|
| Levered Free Cash Flow | -22,189 | -35,664 | -19,635 | 3,426 | -7,354 | Upgrade
|
| Unlevered Free Cash Flow | -19,275 | -33,482 | -17,803 | 4,945 | -7,205 | Upgrade
|
| Change in Net Working Capital | -9,901 | 16,918 | 4,791 | -17,696 | -2,454 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.